Wei-Hua Lan

Dr. Wei-Hua Lan

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QLQiuli Liu
Qiuli Liu
DTDali Tong
Dali Tong
GLGaolei Liu
Gaolei Liu
JXJing Xu
Jing Xu
KDKhang Do
Khang Do
JJJun Jiang
Jun Jiang
Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR antagonist resistance have been focused on AR signaling. Therefore, the non-AR pathways on enzalutamide resistance remain largely unknown. By using C4-2, CWR22Rv1 and LNCaP cell lines, as well as mice bearing CWR22Rv1 xenografts treated with either enzalutamide or metformin alone or in combination, we demonstrated that metformin is capable of reversing enzalutamide resistance and restores sensitivity of CWR22Rv1 xenografts to enzalutamide. We showed that metformin alleviated resistance to enzalutamide by inhibiting EMT. Furthermore, based on the effect of metformin on the activation of STAT3 and expression of TGF-β1, we propose that metformin exerts its effects by targeting the TGF-β1/STAT3 axis. These findings suggest that combination of metformin with enzalutamide could be a more efficacious therapeutic strategy for the treatment of castration-resistant prostate cancer.

10 August 2018 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
DTDali Tong
Dali Tong
QLQiuli Liu
Qiuli Liu
LWLin-Ang Wang
Lin-Ang Wang
QXQiubo Xie
Qiubo Xie
JPJian Pang
Jian Pang
JJJun Jiang
Jun Jiang

15 November 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
QLQiuli Liu
Qiuli Liu
DTDali Tong
Dali Tong
GLGaolei Liu
Gaolei Liu
JGJie Gao
Jie Gao
LWLin-Ang Wang
Lin-Ang Wang
JJJun Jiang
Jun Jiang
Purpose: Inflammatory infiltration plays important roles in both carcinogenesis and metastasis. We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer. Experimental Design: By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, in vitro macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer. Results: Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages. Furthermore, metformin is capable of inhibiting the following processes: inflammatory infiltration after androgen deprivation therapy (ADT) induced by surgically castration in mice, bicalutamide treatment in patients, and hormone deprivation in LNCaP cells. Mechanistically, metformin represses inflammatory infiltration by downregulating both COX2 and PGE2 in tumor cells. Conclusions: Metformin is capable of repressing prostate cancer progression by inhibiting infiltration of tumor-associated macrophages, especially those induced by ADT, by inhibiting the COX2/PGE2 axis, suggesting that a combination of ADT with metformin could be a more efficient therapeutic strategy for prostate cancer treatment. Clin Cancer Res; 1–13. ©2018 AACR.

4 August 2023 in Science Advances
Verified
Journal Article
Open access
SPSong Peng
Song Peng
ZWZe Wang
Ze Wang
PTPeng Tang
Peng Tang
SWShuo Wang
Shuo Wang
YHYiqiang Huang
Yiqiang Huang
QLQiuli Liu
Qiuli Liu
For clear cell renal cell carcinoma (ccRCC), lipid deposition plays important roles in the development, metastasis, and drug resistance. However, the molecular mechanisms underlying lipid deposition in ccRCC remain largely unknown. By conducting an unbiased CRISPR-Cas9 screening, we identified the epigenetic regulator plant homeodomain finger protein 8 (PHF8) as an important regulator in ccRCC lipid deposition. Moreover, PHF8 is regulated by von Hippel–Lindau (VHL)/hypoxia-inducible factor (HIF) axis and essential for VHL deficiency–induced lipid deposition. PHF8 transcriptionally up-regulates glutamate-ammonia ligase (GLUL), which promotes the lipid deposition and ccRCC progression. Mechanistically, by forming a complex with c-MYC, PHF8 up-regulates TEA domain transcription factor 1 (TEAD1) in a histone demethylation–dependent manner. Subsequently, TEAD1 up-regulates GLUL transcriptionally. Pharmacological inhibition of GLUL by l -methionine sulfoximine not only repressed ccRCC lipid deposition and tumor growth but also enhanced the anticancer effects of everolimus. Thus, the PHF8-GLUL axis represents a potential therapeutic target for ccRCC treatment.

18 November 2022 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
ZWZe Wang
Ze Wang
XYXuzhi Yan
Xuzhi Yan
PTPeng Tang
Peng Tang
TTTang Tang
Tang Tang
YWYapeng Wang
Yapeng Wang
QLQiuli Liu
Qiuli Liu

18 March 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
HWHanling Wang
Hanling Wang
SZSulin Zhang
Sulin Zhang
QPQiang Pan
Qiang Pan
JGJiacheng Guo
Jiacheng Guo
NLNi Li
Ni Li
JQJun Qin
Jun Qin